Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Piroxicam (compound)


PubChem
Name: Piroxicam
PubChem Compound ID: 10830762
Description: A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Molecular formula: C15H13N3O4S
Molecular weight: 337.372 g/mol
DrugBank
Identification
Name: Piroxicam
Name (isomeric): DB00554
Drug Type: small molecule
Description: A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Synonyms:
AK1015
Brand: Pipoxicam, Reudene, piroxicam usp, Riacen, Pirkam, Artroxicam, Flogobene, Piroflex, Zunden, Apo-Piroxicam, Improntal, Bruxicam, Baxo, Sasulen, Solocalm, Larapam, Akten, Roxicam, Caliment, Geldene, Erazon, Feldene, Roxiden
Category: Cyclooxygenase Inhibitors
CAS number: 36322-90-4
Pharmacology
Indication: For treatment of osteoarthritis and rheumatoid arthritis.
Pharmacology: Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
Mechanism of Action:
The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the m...
show more »
Absorption: Well absorbed following oral administration.
Biotransformation: Renal
Route of elimination: Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.
Half Life: 30 to 86 hours
Toxicity: Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Take with food. Avoid alcohol.
Drug interaction:
CarteololRisk of inhibition of renal prostaglandins
TamoxifenPiroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed.
AtenololRisk of inhibition of renal prostaglandins
TriflusalThe metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of glisentide to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
PenbutololRisk of inhibition of renal prostaglandins
show more »

Targets


Enzymes


Transporters


Carriers